Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique,
non-viral proprietary platform designed to deliver tumor suppressor genes to
cancer cells, today provided a clinical update and focus for its Oncoprex(TM)
immunogene therapy program for 2020. According to the update, Genprex will
prioritize the development of Oncoprex in combination with osimertinib for the
treatment of non-small cell lung cancer (“NSCLC”). Genprex, on January 14,
2020, received U.S Food and Drug Administration (“FDA”) Fast Track Designation
for its Oncoprex immunogene therapy in combination with the EGFR tyrosine
kinase inhibitor osimertinib (AstraZeneca’s Tagrisso(R), currently its highest
grossing product) for the treatment of NSCLC patients with EFGR mutations that
progressed after treatment with osimertinib alone. Oncoprex consists of the
TUSC2 (“Tumor Suppressor Candidate 2”) gene, the active agent in Oncoprex,
complexed with a lipid nanovesicle.
To view the full press release, visit http://ibn.fm/CiJ9g
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer patients based
upon a unique proprietary technology platform. Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a
multimodal mechanism of action whereby it has been shown to interrupt cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establish pathways for apoptosis, or programmed cell death, in cancer cells,
and modulate the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. In January 2020, the FDA
granted Fast Track Designation for Oncoprex(TM) immunogene therapy for NSCLC in
combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)). For more
information, please visit the company’s web site at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
